Response to the Letter by Tsuboi and Sasaki: “Integrating Podocyte Biology into the Two-Stage Remission Model” Authors: Rutger J Maas, Bartholomeus T van den Berge Published: 2026 To the Editor, We appreciate the insightful comments by Tsuboi and Sasaki1 regarding our recent study. Their proposed “two-stage model” suggests that although partial remission (PR) reflects immunologic responsiveness, the progression to complete remission (CR) is constrained by nephron reserve. In our opinion, the previous data by Sasaki et al2 on the relationship between nephron number and proteinuria response to steroids in minimal change disease suggest that the influence of nephron number is present from the onset of therapy. Their results demonstrated a biphasic reduction in proteinuria: an initial rapid phase followed by a slower reduction phase. Although the time to PR across nephron number tertiles did not reach statistical significance, a numerical trend is evident (7, 9, and 11 days, respectively). We hypothesize that this initial slope is determined by both the abatement of the immunological insult and the patient’s nephron endowment. Consequently, the biological state of immunological remission may not strictly coincide with the clinical achievement of PR, which often occurs during the first rapid phase. This discordance is supported by our recent data on urinary podocyte loss.3 We observed that although some patients reached biological stability—the normalization of urinary podocyte shedding—by the time of PR, others still exhibited significantly elevated loss. This suggests that the “first stage” of remission is more heterogeneous than proteinuria indicates. Regarding the immunological drivers, Hengel et al4 demonstrated that antinephrin-positive patients generally achieve CR and become antibody negative by 8 weeks of steroid treatment. We propose that although the first stage represents the resolution of the immunologic insult, the latter phase is determined by the restoration of the podocyte slit diaphragm. This recovery is dictated by local factors, including functional reserve and podocyte stability. Our biopsy morphometric analysis supports this second phase because we identified nonsclerotic glomerular density and podocyte density as significant predictors of achieving CR. This suggests that even after the immunologic remission occurs, the final transition to CR depends on the structural capacity of the remaining podocyte pool. Therefore, we suggest that integrating biopsy morphometrics with markers of immunologic remission (antinephrin antibodies) and structural stability (normalized podocyturia) represents a potential framework for a more refined, personalized approach to therapy and monitoring that warrants further prospective validation. Article Information Financial Disclosure The authors declare that they have no relevant financial interests. Peer Review Received February 24, 2026. Accepted upon review by the Editor in Chief on February 26, 2026. References